NERV
Price
$1.80
Change
+$0.02 (+1.12%)
Updated
Jun 13 closing price
Capitalization
12.59M
58 days until earnings call
RCKT
Price
$2.93
Change
-$0.14 (-4.56%)
Updated
Jun 13 closing price
Capitalization
315.67M
57 days until earnings call
Interact to see
Advertisement

NERV vs RCKT

Header iconNERV vs RCKT Comparison
Open Charts NERV vs RCKTBanner chart's image
Minerva Neurosciences
Price$1.80
Change+$0.02 (+1.12%)
Volume$6.75K
Capitalization12.59M
Rocket Pharmaceuticals
Price$2.93
Change-$0.14 (-4.56%)
Volume$3.11M
Capitalization315.67M
NERV vs RCKT Comparison Chart
Loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NERV vs. RCKT commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a StrongBuy and RCKT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (NERV: $1.80 vs. RCKT: $2.93)
Brand notoriety: NERV and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NERV: 56% vs. RCKT: 64%
Market capitalization -- NERV: $12.59M vs. RCKT: $315.67M
NERV [@Biotechnology] is valued at $12.59M. RCKT’s [@Biotechnology] market capitalization is $315.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $356.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, NERV is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 5 TA indicator(s) are bullish.

  • RCKT’s TA Score: 5 bullish, 3 bearish.

Price Growth

NERV (@Biotechnology) experienced а -2.17% price change this week, while RCKT (@Biotechnology) price change was -4.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

NERV is expected to report earnings on Aug 12, 2025.

RCKT is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($316M) has a higher market cap than NERV($12.6M). NERV YTD gains are higher at: -18.977 vs. RCKT (-76.691). NERV has higher annual earnings (EBITDA): 6.02M vs. RCKT (-246.03M). RCKT has more cash in the bank: 318M vs. NERV (21.4M). NERV has less debt than RCKT: NERV (0) vs RCKT (25.4M). NERV (0) and RCKT (0) have equivalent revenues.
NERVRCKTNERV / RCKT
Capitalization12.6M316M4%
EBITDA6.02M-246.03M-2%
Gain YTD-18.977-76.69125%
P/E Ratio2.20N/A-
Revenue00-
Total Cash21.4M318M7%
Total Debt025.4M-
FUNDAMENTALS RATINGS
NERV vs RCKT: Fundamental Ratings
NERV
RCKT
OUTLOOK RATING
1..100
4057
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
5298
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (15) in the Biotechnology industry is in the same range as NERV (43). This means that RCKT’s stock grew similarly to NERV’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NERV (100). This means that RCKT’s stock grew similarly to NERV’s over the last 12 months.

RCKT's SMR Rating (94) in the Biotechnology industry is in the same range as NERV (99). This means that RCKT’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for RCKT (98). This means that NERV’s stock grew somewhat faster than RCKT’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as RCKT (100). This means that NERV’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKT
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTRE28.81-0.20
-0.69%
CareTrust REIT
AMRC15.85-0.16
-1.00%
Ameresco
PHG22.75-0.87
-3.68%
Koninklijke Philips NV
PAYS4.86-0.19
-3.76%
Paysign
ARBB6.80-0.45
-6.21%
ARB IOT Group Limited

NERV and

Correlation & Price change

A.I.dvisor tells us that NERV and CVAC have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NERV and CVAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+0.84%
CVAC - NERV
32%
Poorly correlated
-0.54%
DNLI - NERV
32%
Poorly correlated
-2.51%
ANAB - NERV
32%
Poorly correlated
-0.38%
PLRX - NERV
30%
Poorly correlated
-6.12%
RCKT - NERV
30%
Poorly correlated
-4.56%
More